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Abstract
Background: Hepatitis A virus (HAV) and hepatitis E virus (HEV) are both transmitted by the faecal-oral route, and
represent common causes of acute hepatitis in developing countries. The endemicity of HAV infection has shifted
from high to moderate in Brazil. Human cases of HEV infection seem to be rare, although the virus has been
detected in swine livestock and effluents of slaughterhouses. This study was to determine the epidemiology of
hepatitis A and E in one of the largest agricultural settlements in the Amazon Basin of Brazil.
Methods: Serum samples collected from 397 individuals aged between 5 and 90 years during a population-based
cross-sectional survey were tested for anti-HAV and anti-HEV antibodies. Associated risk factors and spatial clustering
of HAV and HEV seropositivity were also analyzed.
Results: The overall rate of HAV seropositivity was 82.9% (95% confidence interval (CI), 79.2-86.6%). Multilevel
logistic regression analysis identified increasing age (in years; odds ratio (OR), 1.097; 95% CI, 1.050-1.147; P < 0.001)
and crowding (OR, 1.603; 95% CI, 1.054-2.440; P = 0.028) as significant risk factors for HAV seropositivity. Anti-HEV
IgG was detected in 50/388 settlers (12.9%, 95% CI, 9.5-16.2%). Anti-HEV IgM was detected in 7/43 (16.3%) anti-IgG
positive samples, and 4 of them had a confirmed result by immunoblot. Increasing age was the only significant
determinant of HEV seropositivity (OR, 1.033; 95% CI, 1.016-1.050; P < 0.001). No significant spatial clustering of HAV
and HEV seropositivity was detected in the area.
Conclusions: Both HAV and HEV are endemic, with differing rates of infection in children and adults in this rural
setting of the Brazilian Amazon. Anti-HEV prevalence was considerably higher than those previously reported in
Brazil. The detection of HEV- specific IgM antibodies in four asymptomatic individuals is highly suggestive of the
circulation of HEV in this rural population.
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Background
Despite significant achievements in recent decades to
control viral hepatitis worldwide, and a considerable pool
of information for prevention, hepatitis A virus (HAV) and
hepatitis E virus (HEV) infections remain as matter of a sig-
nificant public health concern. Both viruses are transmitted
primarily by the faecal-oral route, and cause a disease that
is indistinguishable without serologic testing. However,
HAV and HEV display considerable differences regarding
their nature and epidemiology [1]. Immunity to HAV is
lifelong, and infection often acquired early in life, while
most of the HEV infections occur in late childhood or
young adulthood [2]. Moreover, person-to-person trans-
mission of HEV seems to be less frequent and its preva-
lence, even in endemic areas (7.8% to 45%), not as high as
for HAV infection (up to 100% in low-income countries)
[3,4]. Furthermore, HEV is now recognized as a zoonotic
virus. Several animal sources of HEV have been identified
but swine is considered to be the main reservoir of this
virus [5].
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HAV and HEV show, both, a worldwide distribution.
Their prevalences are very closely related to the level of
economic development and access to safe drinking water
and sanitation [3,4]. HEV is associated with sporadic
cases and epidemic outbreaks of acute hepatitis ─ both
situations related to bad hygiene and sanitary conditions
in the regions where such virus is endemic ─ in many
Asian and African countries [6]. Nevertheless the global
burden of HEV infection is more influenced by sporadic-
ally transmitted hepatitis E cases than by epidemics [4].
In industrialized countries, sporadic cases of HEV infec-
tion were mainly reported in individuals with a history
of traveling to endemic areas. However, indigenous HEV
strains ─ genetically different from those circulating in
endemic areas ─ have been also reported in Europe, New
Zealand, North America, and South America [7-10]. In
fact, autochthonous HEV infection has been detected in
every country in which it has been sought, usually associ-
ated with genotype 3.
In Brazil, the epidemiology of HAV infection has
undergone considerable changes. Many studies recently
conducted, mainly in urban areas, has shown a consist-
ent decrease of the incidence rates in childhood [11-18].
The country now is considered to have an intermediate
level of hepatitis A endemicity [19,20]. Exposure to this
virus has been less frequently investigated in rural pop-
ulations of this country. Previous studies have shown
high seroprevalence rates in riverine populations of the
Amazon Basin [21-24], most likely as a result of poor
sanitation and lack of safe water supply in these com-
munities. However, a recent study carried out in chil-
dren living on the periphery of three Brazilian capital
cities (Rio de Janeiro, Cuiabá and Manaus) showed that a
large number of those under five years old (74.1% - 90%)
were susceptible to HAV infection [16]. In contrast, acute
cases of HEV seem to be infrequent in Brazil [25,26]; the
first (and single) autochthonous human case of acute HEV
infection was reported recently [8]. Among healthy individ-
uals (including blood donors and pregnant women), the
anti-HEV IgG seroprevalence ranged from 1.0% to 7.5%
[27], with no differences among the geographical regions.
Four studies investigated anti-HEV prevalence in the
general population of Amazonian communities [23,28-30],
with rates varying from 3.3% to 6.1%.
Here we describe the epidemiology of human hepatitis
A and E in one of the largest agricultural settlements
in the Amazon Basin of Brazil, the Pedro Peixoto
settlement in the state of Acre. We used a multilevel
approach to analyze individual and household-level
risk factors for the presence of antibodies to HAV and
HEV. In addition, we examine the spatial distribution
of HAV and HEV seropositive subjects, and discuss the
prospects for controlling this infection in this and
other similar rural settings.
Methods
Study area
The state of Acre is located in the Western Amazon Basin
of Brazil, bordering with Peru, Bolivia and the Brazilian
states of Amazonas and Rondônia (Figure 1). The study
site, Ramal do Granada (9°41′S-9°49′S, 67°05′W-67°07′W),
was a sparsely peopled rubber tapper settlement in the east-
ern corner of Acre that became part of the Pedro Peixoto
Agricultural Settlement Project in 1982. The area is charac-
terized by a humid equatorial climate and receives most
rainfall (annual average, 2198.5 mm) between December
and March. The mean annual temperature is 24.5°C. Sub-
sistence agriculture and cattle ranching are currently the
main economic activities, with coffee, banana and rice as
the main cash crops. The high prevalence of intestinal para-
sites in the study population [31] suggests that prevailing
environmental features favour the transmission of enteric
pathogens in this community.
Study population
Recruitment strategies have been described elsewhere
[32]. Briefly, all households enumerated during a census
performed by our field team in Ramal do Granada were
visited between March and April 2004, and 466 dwellers
aged less than one year to 90 years of age (98.5% of the
473 permanent residents in the area found at the time of
the census) were enrolled. An additional 43 individuals
(mostly newcomers to the area) were enrolled between
September and October 2004. The 425 study partici-
pants aged five years or older who were enrolled either
in March-April or September-October 2004 were invited
to contribute a 5-mL venous blood sample for serum
separation; 397 subjects (93.4% of the eligible; age range,
5–90 years; median, 23 years), living in 118 households,
had their sera tested for antibodies to hepatitis A virus
and constituted the main population sample analyzed in
this survey. In addition, 388 out of 397 subjects whose
sera were still available were also examined for antibodies
to HEV. The location of all households was determined
using a hand-held, 12-chanel global positioning system
receiver (eTrexPersonal Navigator, Garmin, Olathe, KS),
which gives a positional accuracy within 15 m. A baseline
questionnaire was applied to study participants to obtain
demographic, clinical and socioeconomic information.
The number of years of schooling of the household head,
the number of persons per room, and the source of water
used for cooking and bathing were recorded. To derive a
wealth index, we also obtained information on: (a) the
ownership of six household assets (gas stove, couch, bicycle,
motor vehicle, and cattle), (b) land tenure (yes or no),
(c) the type of housing material (brick walls vs. others),
and (d) the number of inhabitants per room (≤1 per
room or > 1 per room). Principal component analysis
was used to define weights for each variable. The first
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principal component explained 25.6% of the variability and
gave greatest weight to ownership of a couch (0.670), a mo-
torized vehicle (car or motorcycle) (0.641) and lower num-
ber of inhabitants per room (0.574). Principal component
analysis was carried out using the XLSTAT software, ver-
sion 7.5.2 (Addinsoft, New York, NY). After the standard-
ized variables were weighted, the highest scores were given
to the ownership of a brick house (2.262), a sofa set (1.040)
and a motor vehicle (0.742). Lowest scores were given to
households lacking gas stove (−1.237), with no land tenure
(−1.054), with > 1 inhabitant per room (−0.619) and without
cattle (−0.614). The scores were summed to a wealth index
for each household (range, −4.871 to 5.409).
Serological assays
Serum samples were screened for HAV and HEV specific
IgG antibodies by using the commercial enzyme linked
immunosorbent assays (ELISA): bioELISA HAV IgG and
bioELISA HEV IgG (Biokit, Spain) according to manufac-
turer’s instructions. Reactive samples in the IgG hepatitis E
assay were repeatedly tested and considered positive only if
reactive in duplicate. The anti-HEV IgG reactive samples
were also tested for anti-HEV IgM by using two immuno-
assays, bioELISA HEV IgM (Biokit, Spain) and recomWell
HEV IgM (Mikrogen, Germany). The reactivity of samples
in HEV ELISAs was confirmed by immunoblot assay
(IB) recomLine HEV IgM/IgG (Mikrogen, Germany). Both
Mikrogen assays, ELISA and IB, are based on genotypes 1
and 3, while the bioELISA HEV IgM/IgG contains type-
common recombinant HEV antigens derived from Burmese
and Mexican strains (genotypes 1 and 2 viruses).
Data analysis
A database was created with SPSS 13.0 (SPSS Inc,
Chicago, IL). Prevalence rates are given with exact bino-
mial 95% confidence intervals (95% CI) and compared
with χ2tests or χ2tests for trend; unadjusted odds ratios
were also calculated for potential risk factors. Multiple
logistic regression models with stepwise backward de-
letion were built to describe independent associations
between potential risk factors (independent variables)
and HAV and HEV seropositivity. Variables associated
with P values <0.20 in unadjusted analysis were included
into logistic regression models. Because the data have a
nested structure, where individuals are nested within
households, the assumption of independence of obser-
vations underlying standard logistic regression analysis
is violated. We therefore used two-level logistic models
with individual-level covariates (age, gender, and history
of previous hepatitis) and household-level risk covari-
ates (education of the household head, wealth index,
and source of water for cooking and bathing). The
HML software package (version 6.03, Scientific Software
International, Lincolnwood, IL) was used for multilevel ana-
lysis. Only variables associated with statistical significance at
the 10% level were maintained in the final model.
Figure 1 Location of the municipality of Acrelândia and Settlement Project Director (PAD) Padre Peixoto, known as Ramal do Granada.
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The Kulldorff spatial scan statistics was used to test
whether HAV and HEV seropositivity was randomly
distributed within the study area and, if not, to identify
significant spatial clusters (Kulldorff and Nagarwalla, 1995).
Analysis was made using the Bernoulli model imple-
mented in the version 5.1 of the SaTScan software
(available at: http://www.satscan.org), which creates and
moves circular windows systematically throughout the
geographic space to identify significant clusters of infec-
tions. The windows are centered on each household; the
largest possible cluster would encompass 30% of the
households. For each location and size of the scanning
window, SaTScan performs a likelihood ratio test to
evaluate whether or not HAV and HEV seropositivity is
significantly more prevalent (high-prevalence clusters)
or less prevalent (low-prevalence clusters) within than
outside that given circular window. P values were deter-
mined by 10,000 Monte Carlo replications of the data
set; a level of significance of 5% was adopted.
Ethical considerations
Approval of the study protocol was obtained from the
Ethical Review Board of the Institute of Biomedical Sciences
of the University of São Paulo, Brazil (318/2002). The study
was performed in compliance with relevant laws and
institutional guidelines and in accordance with the ethical
standards of the Declaration of Helsinki. Written informed
consent was obtained from all study participants or their
parents/guardians.
Results
Prevalence of hepatitis A antibodies and associated
risk factors
HAV antibodies were detected in 309 subjects (median,
27 years; interquartile range, 16–40 years), with an overall
seroprevalence rate of 82.9% (95% CI, 79.2-86.6%). The
seroprevalence rate was substantially higher among sub-
jects older than 30 years of age (96.0%) than in preschool
and schoolchildren aged 5–14 years (59.7%), consistent
with most of the enterically transmitted diseases occurring
in early childhood. The seropositivity rate was slightly
higher in females (84.7%) than in males (81.1%), a differ-
ence without statistical significance in unadjusted analysis
(Table 1). No significant association was found between
HAV seropositivity and a past history of hepatitis (Table 1).
No household-level variable was significantly associated
with the presence of HAV antibodies in unadjusted ana-
lysis (Table 1). After adjustment for confounding co-
variates by using two-level logistic regression analysis,
only increasing age, gender and crowding emerged as
significant (P < 0.05) independent predictors of HAV
seropositivity (Table 2). The Kulldorf spatial scan statistic
revealed no significant high or low HAV seroprevalence
cluster in Granada.
Prevalence of hepatitis E antibodies and associated
risk factors
HEV antibodies were detected in 50 subjects, with a me-
dian age higher than that of HAV-seropositive subjects
(median, 31 years; interquartile range, 23–45 years). The
overall HEV positivity rate was 12.9% (95% CI, 9.5-16.2%),
with the highest seroprevalence (19.4%) in young adults
(21–30 years of age) (Table 3). The only household-level
variable significantly associated with the presence of HEV
antibodies in unadjusted analysis was the education of
the household head (Table 3). After adjustment for
confounding covariates by using two-level logistic re-
gression analysis, only young age remained as a signifi-
cant independent predictor of HEV seropositivity, with
an OR of 1.033 (95% CI, 1.016-1.050; P < 0.001), indi-
cating that each additional year of age increased the
odds of having HEV antibodies by 3.3%. The Kulldorf
spatial scan statistic revealed no significant high or low
HEV seroprevalence cluster in Granada.
Of the 50 anti-HEV IgG positive samples, 43 were also
tested for detection of anti-HEV IgM, by ELISA. HEV
IgM antibodies were detected in 7 (16.3%) individuals,
from which 6 samples were still available for additional
testing with the recomLine HEV IgM/IgG immunoblot
(IB) assay. Four of these samples tested positive in the
recomLine HEV IgM/IgG. The two samples that tested
negative by IB showed low (1,3 and 1,6) optical density/
cutoff (OD/CO) ratios. On the other hand, the four IB
positive samples had higher ratios (between 3 and 6).
These four IgM anti-HEV/IB positive individuals (aged 10,
25, 28 and 34 years, and living in the study area since 5 to
19 years) were asymptomatic, and also positive for HAV
IgG antibodies. Regarding the two individuals whose HEV
IgM reactivity was not confirmed by IB, one (Male, 31 years)
had malaria 30 days before blood collection, and positive
serology for Mayaro virus at the time of blood collection;
from the other, data are not available. One presumptive
anti-HEV IgM positive sample (according to the bioELISA
HEV IgM manufacturer’s instructions), which showed very
low (1,1) OD/CO ratio, was from a 38 years old pregnant
woman, with vivax malaria at the time of blood collection.
Discussion
This is the first community-based survey that compares,
in the same population in Brazil, prevalence and risk
factors for HAV and HEV infection. Poor sanitation and
lack of access to safe water usually lead to enteric infections
in early childhood, consistent with the HAV age-prevalence
data described here for the Granada community (Table 1),
and also observed in low socioeconomic status groups in
Brazil [23,28,33,34], and other countries in Latin America
[3,35]. Since we have excluded children below 5 years of age
from the study population (because many children’s parents
or guardian refused to consent a venous blood sample), we
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were unable to estimate the force of HAV infection over the
first years of life in this highly-endemicity area.
Regarding HEV infection, it tends to affect all age
groups in Granada, as observed for other Brazilian commu-
nities [23,28-30,33,36-38], (Table 3). However, the highest
seroprevalence was found in young adults, in agreement
with other HEV seroprevalence studies [2,39]. Of interest,
the rate of anti-HEV IgG seropositivity observed (12.9%)
was substantially higher in comparison to those found in
several subsets of healthy individuals across the Amazon
Basin. Previous studies reported rates of 6% in gold miners
[29], 3.3% in a general population of the Southern Amazon
basin [30], 4.5% in children aged 2 to 9 years old from an
Amazonian municipality in Mato Grosso State [28], and 4%
in riverine communities from the Western Amazon basin
[23]. Anti-HEV IgG rates reported from other Brazilian
Table 1 Prevalence of HAV antibodies according to individual and household-level risk factors
Variable No. of subjectsa HAV antibody prevalence (%) Odds ratio (95% CI) P
Age (years)
5-10 69 46.4 1.00 <0.0001b
11-20 111 80.2 4.68 (2.28-9.61)
21-30 67 95.5 24.67 (6.84-131.24)
31-50 103 97.1 38.54 (10.82-203.18)
>50 47 93.6 16.96 (4.63-91.28)
Sex
Female 190 84.7 1.29 (0.74-2.26) 0.417
Male 207 81.1 1.00
Past history of hepatitis
No 345 81.4 1.00 0.082
Yes 52 93.2 2.73 (0.95-10.79)
Education of household head (years of schooling)
0 81 87.6 2.12 (0.76-6.01) 0.418b
1-4 186 77.4 1.20 (0.52-2.63)
5-8 84 88.1 2.22 (0.80-6.26)
>8 52 76.9 1.00
Wealth index (quartiles)c
1 (poorest) 112 83.0 1.06 (0.47-2.39) 0.973b
2 101 82.2 1.00 (0.44-2.28)
3 100 84.0 1.14 (0.49-2.66)
4 (least poor) 84 82.1 1.00
Water source
Well 375 82.4 1.00 0.462
River/stream 22 90.9 2.14 (0.50-19.27)
Drinking water filtrated or chlorinated
Yes 308 83.4 1.00 0.523
No 73 79.4 0.77 (0.39-1.58)
Crowding (number of inhabitants/room)
<1 168 86.9 1.00 0.930b
1-1.9 187 77.5 0.52 (0.28-0.94)
2-3 18 77.8 0.53 (0.15-2.41)
>3 24 100 Not calculable
Ramal do Granada, Brazil, 2004.
aNumber of individuals differ for some variables, because of missing values.
bPvalues forχ2 tests for linear trend; all other P values are for standard χ2 tests.
cWealth index derived from information on household assets and other socioeconomic data; see the “Subjects, Methods” section.
95% CI, 95% confidence interval.
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regions, as well as from other Latin American countries
including either urban or rural population, ranged from
1% to 10% [27].
It should be mentioned that the performance of diag-
nostic assays for hepatitis E is still a matter of concern,
and may compromise comparison among different HEV
seroprevalence studies [40]. According to Khudyakov
and Kamili [41], it seems that the observed poor con-
cordance among assays for detection of IgG anti-HEV
may be explained by variation in sensitivity rather than
specificity of these assays. However, doubts about the
specificity of these assays also emerged in the last years
[40], which could means that the prevalence record could
actually be higher than the real. As a matter of fact, the
specificity of the available assays can vary widely [42]. For
instances, in blood donors from the United Kingdom anti-
HEV IgG was detected in 3.6% and 16.2% by using different
commercial assays [43]. Similarly, in a setting of patients
with acute HEV infection (with HEV RNA detectable), 44%
of the samples were reactive with one assay and 98% with
the other [42]. It is a general concern that efforts should be
done in order to establish a consensus about the most suit-
able technologie for performing serosurveys. The commer-
cially available assays exhibit varying diagnostic properties
of antigens [41]. Besides, the duration of antibody response
to different HEV epitopes was shown to vary widely [44].
In the present study, one sample (which showed a high
seropositivity of both, bioELISA and recomWELL IgM, and
also, IgG bioELISA) had IgM positive (reactive for O2 and
O3 antigens) but IgG negative results by IB. The opposite
was observed for another sample that were IgG positive
(reactive for O2, but non-reactive for O3 antigen), but IgM
negative by IB. This sample, however, had high ratios of
IgM seropositivity detected by both, commercial (Bioelisa
and Recomwell) immunoassays. Such discrepant results
may reflect the timing of sampling as also described by
others [45].
In general, prevalence of HEV IgG antibodies does not
necessarily reflects the disease prevalence, especially in
regions of low endemicity. However, confirmed reactivity
of anti-HEV IgM is considered diagnostic for acute in-
fection [40]. In the present study, the detection of HEV-
specific IgM antibodies (confirmed by IB) in 9.3% (4/43)
of the samples obtained from a setting of healthy subjects
is highly suggestive of the circulation of HEV in the actual
population.
Among the risk factors considered in determining the
patterns of prevalence in developing countries, age and
crowding emerged as significant contributors to HAV
Table 3 Prevalence of HEV antibodies according to
individual and household-level risk factors
Variable No. of
subjectsa
HEV antibody
prevalence (%)
Odds ratio
(95% CI)
P
Age (years) <0.008b
5-10 66 9.1 1.00
11-20 107 4.7 0.49 (0.11-2.03)
21-30 67 19.4 2.41 (0.78-8.23)
31-50 101 17.8 2.17 (0.76-7.05)
>50 47 17.0 2.05 (0.57-7.72)
Sex
Female 184 14.1 1.23 (0.65-2.34) 0.290
Male 204 11.8 1.00
Past history of hepatitis
No 337 13.3 1.00 0.631
Yes 52 9.8 0.71 (0.21-1.91)
Education of household head (years of schooling) 0.046b
0 81 18.5 2.73 (0.80-11.92)
1-4 174 13.2 1.83 (0.58-7.61)
5-8 81 9.9 1.32 (0.33-6.29)
>8 52 7.7 1.00
Wealth index (quartiles)c
1 (poorest) 109 12.8 1.60 (0.57-4.92) 0.497b
2 98 14.3 1.81 (0.64-5.57)
3 98 15.3 1.96 (0.70-5.99)
4 (least poor) 83 8.4 1.00
Water source
Well 366 13.4 1.00 0.382
River/stream 22 4.5 0.31 (0.01-2.01)
Drinking water filtrated or chlorinated
Yes 302 13.2 1.00 0.961
No 72 13.9 1.06 (0.45-2.30)
Crowding (number of inhabitants/room)
<1 161 13.7 1.00 0.673b
1-1.9 181 12.1 0.87 (0.44-1.73)
2-3 22 18.2 1.40 (0.32-4.83)
>3 24 8.3 0.57 (0.06-2.63)
Ramal do Granada, Brazil, 2004.
aNumber of individuals differ for some variables, because of missing values.
bPvalues forχ2 tests for linear trend; all other P values are for standard χ2 tests.
cWealth index derived from information on household assets and other
socioeconomic data; see the “Subjects, Methods” section.
95% CI, 95% confidence interval.
Table 2 Results of the final multilevel logistic regression
model including variables putatively associated with
HAV antibodies
Variable Odds
ratio
(95% CI) P
Age (in years, continuous variable) 1.097 (1.050-1.147) <0.0001
Sex (male vs. female) 0.594 (0.381-0.929) 0.022
Crowding (number of inhabitants/room) 1.603 (1.054-2.440) 0.028
Ramal do Granada, Brazil, 2004.
95% CI, 95% confidence interval.
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seropositivity in Granada. In contrast with previous
studies conducted in large and heterogeneous Brazilian
cities [46,47], however, neither socioeconomic variables
such as wealth index and educational level of the house-
hold head, nor environmental variables such as access to
safe water, were significantly associated with HAV sero-
positivity in this relatively homogeneous rural commu-
nity. A gender-related difference in HAV seropositivity
rate was observed, although it has been rarely reported
elsewhere. For example, females were found to be more
frequently seropositive for HAV than males in a large
population-based survey in São Paulo, the largest city in
Brazil, but the difference in seroprevalence rates (67.7%
vs.65.5%) did not reach statistical significance [48].
No environmental risk factor was significantly associ-
ated with HEV seroprevalence in Granada. Interestingly,
although the local environmental conditions theoretic-
ally favour the transmission of enteric pathogens (and, in
fact, intestinal parasites are rather frequent in this popu-
lation [31]), our data indicates that in Granada HEV
infection is acquired later than HAV. And, although the
mode of transmission of HEV was not clear, it seems
that the pattern of HEV infection in this rural Amazonian
community is rather related to that observed for HEV
genotype 3 in developed countries, where the majority of
cases, when the source of infection can be determined, oc-
curs due to consumption of contaminated shellfish, under-
cooked pork or wild game and direct exposure to pigs.
HEV genotypes 1 and 2 (HEV1, HEV2) are exclusive of
human beings, restricted to particular geographical areas
(HEV1, Southern and Central Asia, the Far East, and the
Caribbean; HEV1 and-2, Africa), and spread often among
the population as waterborne, open epidemic outbreaks.
Moreover, looking at the patterns of acquisition of anti-
HEV with age among the population from regions
endemic for HEV1, it can be observed that anti-HEV is
acquired earliest in life in regions endemic for HEV1 in
comparison with regions endemic for HEV3 [40]. India,
Malaysia and Southern China displayed anti-HEV rates
among children up to 20-50% [49-51], although similar or
even lower rates than the one reported here (9%) had been
found in India (0.6 – 8.9%) [52]. In Brazil, HEV 3 has been
the only genotype detected, either in acute hepatitis pa-
tients or in pigs [8,51,53,54]. Evidences of HEV circulation
in the Brazilian Amazon and neighboring countries have
been also reported. HEV genotype 3 has been detected in
faecal samples collected from pigs from different areas of
the Pará state, located in Eastern Brazilian Amazon [55],
and in human and swine faecal samples from two rural
communities in southeastern Bolivia [56]. However, the
involvement of HEV genotype 1 could not be ruled-out to-
tally, since it has been already found in infections acquired
locally at Venezuela [57], Uruguay [58], and Cuba [59].
Unfortunately, the study might have been underpowered
in detecting significant associations with specific risk fac-
tors, since data about contact with domestic or wild ani-
mal were not systematically collected. Likewise, the HEV
genotype circulating in Granada could not be identified
because environmental and stool samples were not avail-
able from the studied population.
The prevalence of anti-HAV was much higher than
that observed for anti-HEV, which is consonant with the
profile reported from endemic areas for both viruses. It
has been noted that, even in regions where both viruses
are endemic, the prevalence of HEV is considerable
lower than the observed for HAV [60]. A cross sectional
study in the general population of Tehran, Iran, showed
prevalence rates of HAV and HEV IgG antibodies of 90%
and 9,3%, respectively [61]; in Aden, Yemen, Bawazir et al.
[62] reported anti-HAV and anti-HEV prevalence rates of
86.6% and 10.7%, respectively, among individuals attend-
ing primary health care facilities. Rates of 94.1% and 7.3%
for anti-HAV and anti-HEV were found by Bartoloni et al.
[63] in the population of two rural areas in south-eastern
Bolivia. To which extent these age-structured seropreva-
lence data are affected by a decline in HEV antibody titers
over time which could lead to an underestimation of the
frequency of HEV exposure as previously evidenced
remains to be investigated.
Conclusion
In conclusion, both HAV and HEV infections seemed to
be endemic in this Amazonian community. Even though
the prevalence rate of HEV had been much lower than
the rate observed for HAV, it was considerably higher
than anti-HEV rates previously reported for several
population groups in Brazil. Moreover, the detection of
HEV- specific IgM antibodies in four asymptomatic indi-
viduals is highly suggestive of the circulation of HEV in
this rural population. Further studies are required to
identify specific risk factors that would be involved in
HEV circulation within this tropical Amazonian setting.
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